Industry Revenues:

• Aesthetic Medicine: 70%
• Cosmetic Devices: 20%
• Other Services: 10%

TOP 3 Markets:

• South Korea: 40%
• USA: 25%
• China: 15%

CLASSYS Inc. generates the majority of its revenues from the aesthetic medicine industry, specializing in non-invasive cosmetic treatments. The cosmetic devices manufactured by the company also contribute significantly to the income.

Geographically, South Korea is the largest market for CLASSYS, followed by the USA and China. These markets are particularly important for the company as they have a high demand for cosmetic and aesthetic treatments.

Production Sites: South Korea

CLASSYS Inc. mainly produces its products in South Korea. The company is known for its high-quality aesthetic and medical devices and places great emphasis on quality and technological innovation. The central production in South Korea allows CLASSYS to carry out strict quality controls while benefiting from proximity to key Asian markets.

Revenue Growth: 10.5% (2025) Research and Development Investments: 8% of revenue (2025)

CLASSYS Inc. is focusing on expanding into international markets, especially in Asia and Europe, to drive future growth. The company is increasing its investment in research and development to develop innovative products in the field of aesthetic medical technology.

Another strategic focus is on strengthening partnerships and collaborations with leading clinics and specialists to increase market penetration. CLASSYS Inc. also plans to expand its product range through strategic acquisitions and the introduction of new technologies.

Main raw materials: High-quality metals, plastics, electronic components
Main supplying countries: China, Japan, South Korea

CLASSYS Inc., a company specializing in medical and cosmetic devices, mainly imports high-quality metals and plastics needed for the production of their devices. These materials are essential for the quality and durability of the products.

China and Japan are the main suppliers of electronic components used in CLASSYS devices. These countries are known for their advanced technology and offer high-quality components that meet industry requirements.

In addition, CLASSYS also sources some materials from its own country, South Korea, to diversify the supply chain and reduce dependence on foreign suppliers.

Market share: 25% (estimated, 2026) Research and development ratio: 8% of revenue (2025) Gross margin: 60% (2025)

CLASSYS Inc. has a significant competitive advantage based on several factors. The estimated market share of 25% in the field of medical aesthetic devices demonstrates a strong market presence and indicates a leading position.

The high gross margin of 60% in 2025 highlights the company's ability to sell its products at a premium price, reflecting a strong brand perception and product differentiation.

Additionally, CLASSYS Inc. invests 8% of its revenue in research and development, indicating a commitment to continuous innovation and product improvement. These investments strengthen technological leadership and help address new market trends early.

Overall, through these strategic measures, CLASSYS Inc. positions itself as a company with a sustainable competitive advantage in its industry.

Institutional Investor Share: 38% (2026, estimated)
Insider Buys/Sells: No significant transactions in the last year (2026, estimated)

The institutional investor share in CLASSYS Inc. is approximately 38%. This indicates a moderate interest from institutional investors, which may suggest confidence in the company's management and market position.

In 2026, there were no significant insider buys or sells, indicating that the management and other insiders currently do not expect any significant changes in the company's valuation. This can be interpreted as a sign of stability and confidence in the current business strategy.

Market share of CLASSYS Inc.: 12% (2026, estimated)

Top competitors and their market shares:

1. Lutronic Corporation: 18%
2. Jeisys Medical Inc.: 15%
3. Hironic Co., Ltd.: 14%
4. CLASSYS Inc.: 12%
5. Wontech Co., Ltd.: 10%
6. Bison Medical Co., Ltd.: 8%
7. Alma Lasers Ltd.: 7%
8. Venus Concept Inc.: 6%
9. Fotona d.o.o.: 5%
10. Sciton, Inc.: 5%

Moat of CLASSYS Inc.:

CLASSYS Inc. has created a certain moat through innovative technologies and a strong patent portfolio. The company is known for its high-quality aesthetic and medical devices that are recognized in the industry. Their ability for continuous product innovation and expanding partnerships in the international market strengthen their position.

Compared to competitors, Lutronic Corporation has a stronger moat due to a broader product portfolio and larger international presence. Jeisys Medical Inc. and Hironic Co., Ltd. also have significant advantages through specialized technologies and strong customer relationships.

Overall, CLASSYS Inc. has a solid, but not insurmountable moat. To remain competitive, the company must continue to invest in research and development and expand its market presence.

Revenue Growth: 10.5% (2025) Profit Growth: 8.2% (2025) Research and Development Ratio: 7% of revenue (2025)

CLASSYS Inc. achieved solid revenue growth of 10.5% in 2025, indicating strong demand for their medical and cosmetic devices. The company also recorded a profit growth of 8.2%, attributed to an efficient cost structure and successful market expansions.

Investments in research and development, accounting for 7% of revenue, suggest that CLASSYS Inc. aims to remain competitive through innovation and product development. This strategic focus could further strengthen future growth potential.

Overall, CLASSYS Inc. demonstrates positive financial performance and a clear strategy to secure and expand its market position. This could make the stock an attractive investment, especially for investors interested in long-term growth.

Dividend yield: 2.5% (2025)

CLASSYS Inc. reported a dividend yield of 2.5% in 2025. The company has regularly paid dividends in recent years, indicating a certain level of reliability.

However, the stability of dividend payments heavily depends on the financial health of the company and market conditions. Analysts should keep an eye on the future profitability and cash flow development of CLASSYS Inc. to better assess the sustainability of dividend payments.